What are treatment triggers for employing disease-modifying anti-rheumatic drugs (DMARDs)? What classes of biologic agents -- including IL-6 inhibitors -- have demonstrated efficacy as monotherapy?

What are treatment triggers for employing disease-modifying anti-rheumatic drugs (DMARDs)? What classes of biologic agents -- including IL-6 inhibitors -- have demonstrated efficacy as monotherapy?

What are accepted treatment triggers for employing disease-modifying anti-rheumatic drugs (DMARDs)? And what classes of biologic agents — including IL-6 inhibitors and others — have demonstrated efficacy as monotherapy?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Peter Nash, MD

Peter Nash, MD

Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia